These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 36494581

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y, Cao XY, Li YN, Qiu YY, Li YN, Li W, Wang H.
    Am J Physiol Cell Physiol; 2018 Aug 01; 315(2):C225-C235. PubMed ID: 29719173
    [Abstract] [Full Text] [Related]

  • 6. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
    Gao Y, Huang Y.
    J Chemother; 2023 Apr 01; 35(2):117-130. PubMed ID: 35380509
    [Abstract] [Full Text] [Related]

  • 7. Promoting action of long non-coding RNA small nucleolar RNA host gene 4 in ovarian cancer.
    Liu C, Zhao S, Lv ZX, Zhao XJ.
    Acta Biochim Pol; 2023 Jan 19; 70(1):59-68. PubMed ID: 36657061
    [Abstract] [Full Text] [Related]

  • 8. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
    Wu Y, Wang T, Xia L, Zhang M.
    Cancer Cell Int; 2021 May 29; 21(1):284. PubMed ID: 34051810
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3β and inactivating the Wnt/β-catenin signaling pathway.
    Liu S, Wang Q, Liu Y, Xia ZY.
    J Biosci; 2019 Sep 29; 44(4):. PubMed ID: 31502580
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Enhancing wound healing and overcoming cisplatin resistance in ovarian cancer.
    Zhang Q, Guo F, Liu H, Hong L.
    Int Wound J; 2024 Apr 29; 21(4):e14569. PubMed ID: 38158767
    [Abstract] [Full Text] [Related]

  • 17. Exosomal miR-21-5p derived from cisplatin-resistant SKOV3 ovarian cancer cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1.
    Zhuang L, Zhang B, Liu X, Lin L, Wang L, Hong Z, Chen J.
    Cell Biol Int; 2021 Oct 29; 45(10):2140-2149. PubMed ID: 34288231
    [Abstract] [Full Text] [Related]

  • 18. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
    Hu Z, Cai M, Zhang Y, Tao L, Guo R.
    Cell Cycle; 2020 Jan 29; 19(2):193-206. PubMed ID: 31885310
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. DDP-resistant ovarian cancer cells-derived exosomal microRNA-30a-5p reduces the resistance of ovarian cancer cells to DDP.
    Liu R, Zhang Y, Sun P, Wang C.
    Open Biol; 2020 Apr 29; 10(4):190173. PubMed ID: 32343928
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.